NextRNA Therapeutics

Our CEO Dominique Verhelle participated in a panel discussion yesterday focused on non-coding RNA (ncRNA) and epigenetics at the #DarkGenomeSymposium in NYC.?Dominique shared NextRNA's therapeutic approach, which is centered on inhibiting the function of long non-coding RNAs (lncRNAs) by disrupting the interaction between lncRNAs and RNA-binding proteins with small molecules. We're excited to be an industry pioneer in the broad, emerging dark genome field, and a leader in interrogating and translating the potential of lncRNAs to address significant unmet needs in oncology and neuroscience.?? #lncRNA #ncRNA #RNA #darkgenome #DGS2024

Our team recently set sail for an unforgettable team-building adventure in Newport, RI, where we raced 12-meter America's Cup sailboats! It was not only an amazing experience navigating the open waters together but also a celebration of our new strategic collaboration with Bayer and warm welcome to our newest employees. Although we didn't have the expected wind for the race, the calm seas gave us the perfect chance to unwind, connect, and enjoy the day. As we worked together to adjust the sails and navigate the course, we truly embodied the essence of our company: teamwork, resilience, and a shared determination to always move forward. Here's to welcoming new faces, embracing fresh challenges, and celebrating many more victories ahead—both on and off the water! #TeamBuilding #NewportRI #AmericasCup #LeadershipInAction #Sailing #Teamwork #CompanyCulture

I look forward to participating in this partnership-focused panel at the Longwood Healthcare Leaders Boston CEO forum next week to discuss how NextRNA and Bayer's collaboration is reflective of each organization's respective mission and strategy, and how our two organizations are working to shape a true collaboration, where each party has important contributions to ensure its success.

Check out this fascinating article by?Juergen Eckhardt in?Forbes that explores how long non-coding RNAs (lncRNAs) have increasingly been implicated in complex diseases, how lncRNAs interact with RNA-binding proteins (RBPs) to drive pathogenic processes, and how small molecule drugs designed to disrupt these lncRNA-RBP interactions may represent a new class of treatments for many previously intractable diseases, including difficult-to-treat cancers and neurological diseases. https://lnkd.in/eQ3QSb4x #ncRNAs #smallmolecules #biotechinnovation

Our Co-Founder and CEO, Dominique Verhelle, will participate in a panel on Oct. 28 at 4:10pm at the Longwood Healthcare Leaders Boston CEO forum, titled "Aligning Priorities for the Partnership." As part of the discussion, Dominique will share her insights on structuring innovation-driving partnerships to advance first-in-class cancer therapies through the lens of NextRNA's recently announced strategic collaboration with Bayer to develop small molecules targeting long non-coding RNAs (lncRNAs) in oncology. For more information and to register visit: https://lnkd.in/eehfZ2xB #longwoodhealthcareleaders

We’re excited to announce the appointment of Jesse Smith as NextRNA’s Chief Scientific Officer! With his deep expertise in pioneering first-in-class targeted small molecule therapies, Dr. Smith is ideally suited to lead our scientific organization. At NextRNA we are focused on inhibiting the function of disease-driving lncRNAs with small molecules. With our unique platform and capabilities, we have the potential to address multiple high unmet diseases and deliver transformative medicines for patients. Welcome to the NextRNA team, Jesse! Read press release: https://bit.ly/4eiFGUD #RNA #smallmolecule #drugdiscovery #drugdevelopment #lncRNA #darkgenome

Our Co-Founder & CEO, Dominique Verhelle, will give a corporate presentation on Monday, Sep. 30th at 1:30 pm ET at Chardan’s 8th Annual Genetic Medicines Conference in NYC. There is increasing evidence that lncRNAs are implicated in the pathogenesis of a broad spectrum of diseases. With our unique platform and capabilities, NextRNA is well positioned to discover new lncRNA targets and develop transformative small molecule medicines for patients. We look forward to discussing our progress as a leader in the rapidly emerging lncRNA space at #ChardanGMConf! #RNA #smallmolecule #lncRNA #darkgenome

At NextRNA, we believe in the power of community and the importance of supporting and empowering women. Recently, a group of our amazing employees had the honor of volunteering at Rosie's Place, a sanctuary for poor and homeless women in Boston. Together, we served meals, provided support, and contributed to an incredible organization that uplifts women every day. ?? When we empower women, we strengthen our community and fuel a brighter future for everyone. Thank you, Rosie’s Place, for the vital work you do, and thank you to our volunteers for making an impact! #EmpoweringWomen #VolunteerWork #Community #CompanyValues #RosiesPlace #WomenSupportingWomen #GivingBack

Thank you, Labiotech.eu, for speaking with our CEO and Co-Founder Dominique Verhelle about what lncRNAs are, the key role they play across numerous diseases, and the increasing interest in lncRNAs as a therapeutic target class. Read article:?https://lnkd.in/gRH-PC_J